Yale University

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Icahn School of Medicine at Mount Sinai

The United States Government As Represented by the Department of Veterans Affairs

John H Krystal

Gerard Sanacora

Dennis S Charney

Vladimir Coric

Carlos A Zarate

Husseini K Manji

Sanjay J Mathew

Chadi Abdallah

Ronald Duman

John P Seibyl

Vladmir Coric

The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.

Combination therapy for treating or preventing depression or other mood diseases

Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.

Glutamate agents in the treatment of mental disorders

Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (&#x3e;2 years).

Intranasal administration of ketamine to treat depression

Methods for treating suicidal ideation

Mazindol and other dopamine and/or noradrenergic reuptake inhibitors are effective to treat negative symptoms in schizophrenia.

Dopamine and noradrenergic reuptake inhibitors in treatment of

Growing community of inventors

Woodbridge, CT, United States of America

John H Krystal